BRAF, KRAS and EGFR Mutation Detection in Non-Small Cell Lung Cancer Patients Treated With Sorafenib Monotherapy
OBJECTIVES:
- To determine the mutation rates of BRAF, KRAS, and EGFR in patients with non-small cell
lung cancer treated with sorafenib tosylate on protocol ECOG-2501.
- To determine the association between BRAF, KRAS, or EGFR mutation status and clinical
benefits in patients treated with this regimen.
OUTLINE: This is a multicenter study.
DNA is isolated from archived plasma samples and analyzed for BRAF, KRAS, and EGFR
mutations.
Observational
N/A
Mutation rate of sorafenib tosylate-target gene BRAF, and its upstream proteins KRAS and EGFR
No
Christine Chung, MD
Principal Investigator
Vanderbilt-Ingram Cancer Center
Unspecified
CDR0000670998
NCT01124669
June 2010
Name | Location |
---|